Advertisement

Rekindling Hope for Remission

Current Impact of Diabetes for Our World’s Future Health and Economy
Published:November 17, 2022DOI:https://doi.org/10.1016/j.ecl.2022.06.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. United Nations General Assembly. General Assembly adopts resolution stressing cooperation for universal economic development as it acts on over 40 second committee reports. Resolution adopted by the Sixty-first General Assembly, GA/10564 Plenary, 83rd Meeting on 20 December 2006: World Diabetes Day Resolution No. A/RES/61/2252007. Available at: https://www.un.org/press/en/2006/ga10564.doc.htm. Accessed July 16, 2022.

        • Mulder H.
        • Fall T.
        The COVID-19 pandemic may be receding but the diabetes pandemic rages on.
        Diabetologia. 2022; 65: 915-916
        • International Diabetes Federation
        IDF diabtes atlas.
        10th edition. International Diabetes Federation, Brussels2021 (Available at:) (Accessed May 22, 2022)
        • Williams R.
        The costs of diabetes.
        1st edition. International Diabetes Federation, Brussels, Belgium2000: 225-231
        • Wang H.
        • Naghavi M.
        • Allen C.
        • et al.
        Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.
        Lancet. 2016; 388: 1459-1544
        • Spencer Bonilla G.
        • Rodriguez-Gutierrez R.
        • Montori V.M.
        What we don't talk about when we talk about preventing type 2 diabetes-addressing socioeconomic disadvantage.
        JAMA Intern Med. 2016; 176: 1053-1054
        • Williams R.
        • Van Gaal L.
        • Lucioni C.
        • et al.
        Assessing the impact of complications on the costs of Type II diabetes.
        Diabetologia. 2002; 45: S13-S17
        • American Diabetes Association
        Economic costs of diabetes in the US in 2017.
        Diabetes Care. 2018; 41: 917-928
        • Riddle M.C.
        • Cefalu W.T.
        • Evans P.H.
        • et al.
        Consensus report: definition and interpretation of remission in type 2 diabetes.
        Diabetes Care. 2021; 44: 2438-2444
        • Bommer C.
        • Heesemann E.
        • Sagalova V.
        • et al.
        The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.
        Lancet Diabetes Endocrinol. 2017; 5: 423-430
        • Bommer C.
        • Sagalova V.
        • Heesemann E.
        • et al.
        Global economic burden of diabetes in adults: projections from 2015 to 2030.
        Diabetes Care. 2018; 41: 963-970
        • Pohlmann J.
        • Norrbacka K.
        • Boye K.S.
        • et al.
        Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.
        Eur J Health Econ. 2020; 21: 1179-1196
        • Chevreul K.
        • Durand-Zaleski I.
        • Bahrami S.B.
        • et al.
        France: Health system review.
        Health Syst Transit. 2010; 12 (xxi-xxii): 1-291
        • Busse R.
        • Blumel M.
        Germany: Health system review.
        Health Syst Transit. 2014; 16 (xxi): 1-296
        • Ferre F.
        • de Belvis A.G.
        • Valerio L.
        • et al.
        Italy: health system review.
        Health Syst Transit. 2014; 16: 1-168
        • Charbonnel B.
        • Simon D.
        • Dallongeville J.
        • et al.
        Direct medical costs of type 2 diabetes in france: an insurance claims database analysis.
        Pharmacoecon Open. 2018; 2: 209-219
        • Jacobs E.
        • Hoyer A.
        • Brinks R.
        • et al.
        Healthcare costs of Type 2 diabetes in Germany.
        Diabet Med. 2017; 34: 855-861
        • Marcellusi A.
        • Viti R.
        • Mecozzi A.
        • et al.
        The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
        Eur J Health Econ. 2016; 17: 139-147
        • Turchetti G.
        • Bellelli S.
        • Amato M.
        • et al.
        The social cost of chronic kidney disease in Italy.
        Eur J Health Econ. 2017; 18: 847-858
        • Kahm K.
        • Laxy M.
        • Schneider U.
        • et al.
        Health care costs associated with incident complications in patients with type 2 diabetes in Germany.
        Diabetes Care. 2018; 41: 971-978
        • Bongiovanni I.
        • Couillerot-Peyrondet A.L.
        • Sambuc C.
        • et al.
        [Cost-effectiveness analysis of various strategies of end-stage renal disease patients' care in France].
        Nephrol Ther. 2016; 12: 104-115
        • Veronese G.
        • Marchesini G.
        • Forlani G.
        • et al.
        Costs associated with emergency care and hospitalization for severe hypoglycemia.
        Nutr Metab Cardiovasc Dis. 2016; 26: 345-351
        • Mao W.
        • Yip C.W.
        • Chen W.
        Complications of diabetes in China: health system and economic implications.
        BMC Public Health. 2019; 19: 269
        • Yang W.
        • Lu J.
        • Weng J.
        • et al.
        Prevalence of diabetes among men and women in China.
        N Engl J Med. 2010; 362: 1090-1101
        • Hu H.
        • Sawhney M.
        • Shi L.
        • et al.
        A systematic review of the direct economic burden of type 2 diabetes in China.
        Diabetes Ther. 2015; 6: 7-16
        • Yang G.
        • Kong L.
        • Zhao W.
        • et al.
        Emergence of chronic non-communicable diseases in China.
        Lancet. 2008; 372: 1697-1705
        • Chan J.C.
        • Malik V.
        • Jia W.
        • et al.
        Diabetes in Asia: epidemiology, risk factors, and pathophysiology.
        JAMA. 2009; 301: 2129-2140
        • Yajnik C.S.
        Nutrient-mediated teratogenesis and fuel-mediated teratogenesis: two pathways of intrauterine programming of diabetes.
        Int J Gynaecol Obstet. 2009; 104: S27-S31
        • Fujiyoshi P.T.
        • Michalek J.E.
        • Matsumura F.
        Molecular epidemiologic evidence for diabetogenic effects of dioxin exposure in U.S. Air Force veterans of the Vietnam war.
        Environ Health Perspect. 2006; 114: 1677-1683
        • Lee D.H.
        • Steffes M.W.
        • Jacobs Jr., D.R.
        Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes?.
        Diabetologia. 2008; 51: 402-407
        • Chen C.J.
        • Wang S.L.
        • Chiou J.M.
        • et al.
        Arsenic and diabetes and hypertension in human populations: a review.
        Toxicol Appl Pharmacol. 2007; 222: 298-304
        • Haghravan S.
        • Mohammadi-Nasrabadi F.
        • Rafraf M.
        A critical review of national diabetes prevention and control programs in 12 countries in Middle East.
        Diabetes Metab Syndr. 2021; 15: 439-445
        • Mapa-Tassou C.
        • Katte J.C.
        • Mba Maadjhou C.
        • et al.
        Economic impact of diabetes in Africa.
        Curr Diab Rep. 2019; 19: 5
        • Urakami T.
        • Kuwabara R.
        • Yoshida K.
        Economic impact of diabetes in Japan.
        Curr Diab Rep. 2019; 19: 2
        • Arredondo A.
        • Reyes G.
        Health disparities from economic burden of diabetes in middle-income countries: evidence from Mexico.
        PLoS One. 2013; 8: e68443
        • Arredondo A.
        • Azar A.
        • Recaman A.L.
        Diabetes, a global public health challenge with a high epidemiological and economic burden on health systems in Latin America.
        Glob Public Health. 2018; 13: 780-787
        • Centers for Disease Control and Prevention
        National diabetes prevention program. centers for disease control and prevention.
        (Available at:) (Accessed May 22, 2022)
        • Williams R.
        • Karuranga S.
        • Malanda B.
        • et al.
        Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
        Diabetes Res Clin Pract. 2020; 162: 108072
        • Centers for Disease Control and Prevention
        Type 2 diabetes. centers for disease control and prevention.
        (Available at:) (Accessed May 10, 2022)
        • Zhuo X.
        • Zhang P.
        • Hoerger T.J.
        Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.
        Am J Prev Med. 2013; 45: 253-261
        • Coresh J.
        • Astor B.C.
        • Greene T.
        • et al.
        Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.
        Am J Kidney Dis. 2003; 41: 1-12
        • Armstrong D.G.
        • Swerdlow M.A.
        • Armstrong A.A.
        • et al.
        Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer.
        J Foot Ankle Res. 2020; 13: 16
        • Li R.
        • Bilik D.
        • Brown M.B.
        • et al.
        Medical costs associated with type 2 diabetes complications and comorbidities.
        Am J Manag Care. 2013; 19: 421-430
        • Guo J.J.
        • Gibson J.T.
        • Gropper D.M.
        • et al.
        Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
        Am J Manag Care. 1998; 4: 1433-1446
        • Einarson T.R.
        • Bereza B.G.
        • Acs A.
        • et al.
        Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes.
        Curr Med Res Opin. 2017; 33: 331-358
        • Ali M.K.
        • Wharam F.
        • Kenrik Duru O.
        • et al.
        Advancing health policy and program research in diabetes: findings from the Natural Experiments for Translation in Diabetes (NEXT-D) Network.
        Curr Diab Rep. 2018; 18: 146
        • Pierse T.
        • O'Neill S.
        • Dinneen S.F.
        • et al.
        A simulation study of the economic and health impact of a diabetes prevention programme in Ireland.
        Diabet Med. 2021; 38: e14540
        • Nuckols T.K.
        • Keeler E.
        • Anderson L.J.
        • et al.
        Economic evaluation of quality improvement interventions designed to improve glycemic control in diabetes: a systematic review and weighted regression analysis.
        Diabetes Care. 2018; 41: 985-993
        • Teljeur C.
        • Moran P.S.
        • Walshe S.
        • et al.
        Economic evaluation of chronic disease self-management for people with diabetes: a systematic review.
        Diabet Med. 2017; 34: 1040-1049
        • Lee J.Y.
        • Lee S.W.H.
        Telemedicine cost-effectiveness for diabetes management: a systematic review.
        Diabetes Technol Ther. 2018; 20: 492-500
        • Cohen L.B.
        • Taveira T.H.
        • Wu W.C.
        • et al.
        Pharmacist-led telehealth disease management program for patients with diabetes and depression.
        J Telemed Telecare. 2020; 26: 294-302
        • Dadwani R.S.
        • Laiteerapong N.
        Economic simulation modeling in type 2 diabetes.
        Curr Diab Rep. 2020; 20: 24
        • Gunter K.E.
        • Peek M.E.
        • Tanumihardjo J.P.
        • et al.
        Population health innovations and payment to address social needs among patients and communities with diabetes.
        Milbank Q. 2021; 99: 928-973
        • O'Brien C.L.
        • Ski C.F.
        • Thompson D.R.
        • et al.
        The Mental Health in Diabetes Service (MINDS) to enhance psychosocial health: study protocol for a randomized controlled trial.
        Trials. 2016; 17: 444
        • Saulsberry L.
        • Peek M.
        Financing diabetes care in the U.S. health system: payment innovations for addressing the medical and social determinants of health.
        Curr Diab Rep. 2019; 19: 136
        • Marsh K.
        • Ganz M.
        • Nortoft E.
        • et al.
        Incorporating environmental outcomes into a health economic model.
        Int J Technol Assess Health Care. 2016; 32: 400-406
        • Kahn L.G.
        • Philippat C.
        • Nakayama S.F.
        • et al.
        Endocrine-disrupting chemicals: implications for human health.
        Lancet Diabetes Endocrinol. 2020; 8: 703-718